Darren M Moss
Overview
Explore the profile of Darren M Moss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Wolf E, Abdullah M, Jones S, Menezes K, Moss D, Drijfhout F, et al.
Sci Rep
. 2017 Jul;
7(1):5410.
PMID: 28710496
Pre-clinical and retrospective studies of patients using statins to reduce plasma cholesterol have suggested that statins may be useful to treat cancer. However, prospective clinical trials have yet to demonstrate...
2.
Moss D, Domanico P, Watkins M, Park S, Randolph R, Wring S, et al.
Antimicrob Agents Chemother
. 2017 Apr;
61(7).
PMID: 28416547
Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir, has oral bioavailability (25%) limited by intestinal transport (P-glycoprotein), and intestinal degradation (carboxylesterase). However, the influence of luminal pancreatic enzymes is not...
3.
Curley P, Rajoli R, Moss D, Liptrott N, Letendre S, Owen A, et al.
Antimicrob Agents Chemother
. 2016 Nov;
61(1).
PMID: 27799216
Adequate concentrations of efavirenz in the central nervous system (CNS) are necessary to suppress viral replication, but high concentrations may increase the likelihood of CNS adverse drug reactions. The aim...
4.
Curley P, Siccardi M, Moss D, Owen A
Bioanalysis
. 2016 Sep;
8(20):2125-34.
PMID: 27611731
Aim: The non-nucleoside reverse transcriptase inhibitor efavirenz is one of the most prescribed antiretroviral therapeutics. Efavirenz-containing therapy has become associated with the occurrence of CNS side effects, including sleep disturbances,...
5.
Moss D, Liptrott N, Siccardi M, Owen A
Front Pharmacol
. 2015 Apr;
6:78.
PMID: 25914645
The SLC22A1 influx transporter is expressed on the basolateral membrane of hepatocytes and is involved in the excretion of numerous cations. Inhibition of SLC22A1 by several antiretrovirals, such as the...
6.
Moss D
Front Pharmacol
. 2015 Feb;
6:18.
PMID: 25708098
[This corrects the article on p. 248 in vol. 5, PMID: 25426075.].
7.
Moss D, Neary M, Owen A
Front Pharmacol
. 2014 Nov;
5:248.
PMID: 25426075
Tenofovir disoproxil fumarate, the prodrug of nucleotide reverse transcriptase inhibitor tenofovir, shows high efficacy and relatively low toxicity in HIV patients. However, long-term kidney toxicity is now acknowledged as a...
8.
Moss D, Curley P, Shone A, Siccardi M, Owen A
J Antimicrob Chemother
. 2014 Aug;
69(12):3275-81.
PMID: 25114168
Objectives: Recent clinical data have suggested high raltegravir concentrations in gut tissue after oral administration, with implications for treatment and prevention. We have used in silico, in vitro, ex vivo...
9.
Moss D, Liptrott N, Curley P, Siccardi M, Back D, Owen A
Antimicrob Agents Chemother
. 2013 Sep;
57(11):5612-8.
PMID: 24002095
Rilpivirine is a nonnucleoside reverse transcriptase inhibitor approved for treatment of HIV-1 infection in antiretroviral-naive adult patients. Potential interactions with drug transporters have not been fully investigated. Transport by and...
10.
Moss D, Siccardi M, Back D, Owen A
J Antimicrob Chemother
. 2013 Mar;
68(7):1627-34.
PMID: 23515248
Objectives: Raltegravir pharmacokinetics (PK) show high intra- and inter-patient variability and are also influenced by co-administered substances that alter the gastrointestinal tract environment, such as pH-altering or metal-containing agents. The...